A plasma inhibitor of platelet aggregation in patients with Lassa fever.
about
Human platelets and their capacity of binding viruses: meaning and challenges?Pathogenic mechanisms involved in the hematological alterations of arenavirus-induced hemorrhagic feversJunín virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling.Platelets and infection - an emerging role of platelets in viral infection.Platelets and infections in the resource-limited countries with a focus on malaria and viral haemorrhagic fevers.Effective vaccine for lassa fever.Lassa fever: epidemiology, clinical features, and social consequences.Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections.LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration.Pathogenesis of arenavirus hemorrhagic fevers.Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidateThe role of platelets in the pathogenesis of viral hemorrhagic feversGenomic profiling of host responses to Lassa virus: therapeutic potential from primate to manLassa virus.Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus.Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.Review: Viral infections and mechanisms of thrombosis and bleeding.Exchange transfusion of a patient with fulminant Lassa fever.Platelets: much more than bricks in a breached wall.Early blood profiles of virus infection in a monkey model for Lassa fever.Gene expression in primate liver during viral hemorrhagic fever.Pichinde virus-induced respiratory failure due to obstruction of the small airways: structure and function.Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.
P2860
Q26997803-D583C951-BA6F-44C4-BAA4-3CEA058FE47FQ27024900-41E8AB7E-A979-4389-B7B9-EEE6F6BB381DQ33389296-09486C91-3277-42E5-BEA3-C93B79BB9D7DQ33419642-F4E7E183-D052-40A2-AAF7-4FB4F94F5D3BQ33440142-FD602FB1-E3ED-49F0-B7DD-A68204DAD66FQ33808492-CA8018E9-09D8-49C4-8B31-D24AACDD7212Q33822092-71A539F3-883B-4075-9826-46CA6742393BQ33887328-88A41C7C-F8A4-4E79-84A4-930E21D13086Q34338137-9D59F843-F4CB-4BA6-8FEB-129D6817ADB4Q34625899-6CCACC93-625C-46C3-A9DC-3807A1A91842Q34999818-DA7C21BD-AFB3-440D-B53F-08A039721EFEQ35186543-B96642C5-B5A8-4D91-9958-58FBFD6AFCD1Q35248863-29EE6268-A5F6-450B-9E03-F42F77B108CDQ35919691-6DFD954F-4A5D-4535-9C6B-DE908FB20ECBQ36681272-27ABBC4A-5B9E-499C-A3A5-FF46CCBBBA9BQ37912497-9D176B23-FD4D-4FAA-A8E1-26766AF462BCQ38038832-1D99C524-177A-40D9-B71D-448F6D5ABBCCQ38650789-7382EC00-ACDB-4553-AA75-1263A27F8925Q39248498-B6966E3E-58D4-4E07-B88D-D714A25C71C0Q40210245-3093AD29-AADF-4B57-AC83-AA3247AB86F6Q40397175-D4C412F2-48B2-43B3-BDC9-F81120278FE3Q40710462-35762941-B8A5-4252-8373-A6B8D6C1778AQ41929865-46306F9D-76B6-451E-A67D-6FF5E134C58D
P2860
A plasma inhibitor of platelet aggregation in patients with Lassa fever.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
A plasma inhibitor of platelet aggregation in patients with Lassa fever.
@en
type
label
A plasma inhibitor of platelet aggregation in patients with Lassa fever.
@en
prefLabel
A plasma inhibitor of platelet aggregation in patients with Lassa fever.
@en
P2093
P2860
P1476
A plasma inhibitor of platelet aggregation in patients with Lassa fever.
@en
P2093
Fisher-Hoch SP
McCormick JB
P2860
P304
P356
10.1111/J.1365-2141.1989.TB04321.X
P407
P577
1989-08-01T00:00:00Z